Logo

PharmaShots Weekly Snapshots (March 26 – March 29, 2024)

Share this

PharmaShots Weekly Snapshots (March 26 – March 29, 2024)

This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:

Axsome Therapeutics Reports P-III Results of AXS-12 for the Treatment of Narcolepsy 

Read More: Axsome Therapeutics                                                                       

SELLAS Reports P-IIa Results of SLS009 for the Treatment of Acute Myeloid Leukemia (AML) 

Read More: SELLAS                                                                                           

Novocure Reveals the P-III (METIS) Study Results of Stereotactic Radiosurgery in NSCLC Patients

Read More: Novocure                                                                                      

Immuneering Doses First Patient with IMM-6-415 in the P-I/IIa Clinical Evaluation for Treating Advanced Solid Tumors 

Read More: Immuneering                                                                       

BMS Reveals Data from the P-III (KRYSTAL-12) Trial of Krazati as a Treatment of Non-Small Cell Lung Cancer

Read More: BMS                                                                                         

InnoCare Doses First Patient with ICP-189 in the P-Ib Clinical Evaluation to Treat Non-Small Cell Lung Cancer

Read More: InnoCare                                                                                 

The US FDA Grants Approval to Johnson & Johnson’s Opsynvi (macitentan and tadalafil) for the Treatment of Pulmonary Arterial Hypertension

Read More: Johnson & Johnson                                        

The US FDA Grants Approval to Merck’s Winrevair (sotatercept-csrk) for the Treatment of Pulmonary Arterial Hypertension (PAH)

Read More: Merck                                                                          

The US FDA Grants Approval to AstraZeneca’s Ultomiris (ravulizumab-cwvz) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Read More: AstraZeneca                                                            

The MHLW Grants Approval to Takeda’s Adzynma (apadamtase alfa/cinaxadamtase alfa) for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Read More: Takeda                                                                         

The NMPA Accepts HUTCHMED’s sNDA for Savolitinib to Treat NSCLC Associated with MET Exon 14 Mutations

Read More: HUTCHMED                                                                             

The EC Approves Merck’s Keytruda Combined with Chemotherapy for Treating Non-Small Cell Lung Cancer

Read More: Merck                                                                                    

The NMPA Accepts Astellas and Pfizer’s sBLA for Enfortumab Vedotin Plus Keytruda for Treating Bladder Cancer

Read More: Astellas & Pfizer                                                                           

AbbVie Acquires Landos Biopharma for an Aggregate of $212.5M

Read More: AbbVie & Landos Biopharma                                                                                     

Novo Nordisk Acquires Cardior Pharmaceuticals for an Aggregate of ~$1.11B

Read More: Novo Nordisk & Cardior Pharmaceuticals                                                                           

Juvisé Pharmaceuticals Acquires Actelion’s Ponvory (ponesimod) for the Treatment of Multiple Sclerosis (MS)

Read More: Juvisé Pharmaceuticals & Actelion Pharmaceutical             

Verge Genomics Enters into a Collaboration Agreement with Ferrer for the Development and Commercialization of VRG50635 to Treat Amyotrophic Lateral Sclerosis (ALS) 

Read More: Verge Genomics & Ferrer                                                                                             

ABVC BioPharma and ForSeeCon Eye Corporation (FEYE) Entered into a Global Licensing Agreement for the Development and Commercialization of Various Ophthalmology Products 

Read More: ABVC BioPharma & ForSeeCon Eye Corporation                     

Primrose Bio and Intravacc Join Forces to Develop Conjugate Vaccine

Read More: Primrose Bio & Intravacc                                                           

GenFleet and BeiGene Join Forces to Conduct P-Ib/II Study of GFH009 and Brukinsa for Treating Diffuse Large B Cell Lymphoma

Read More: GenFleet & BeiGene                                                       

Gilead Collaborates with Xilio Therapeutics to Develop XTX301 for Treating Wide Range of Cancers

Read More: Gilead & Xilio                                                         

Health Canada Grants Approval to Innodem Neuroscience’s ETNA-MS for the Treatment of Multiple Sclerosis (MS)

Read More: Innodem Neuroscience                                                                                                    

The US FDA Approves Medtronic’s Evolut TAVR System for the Treatment of Aortic Stenosis

Read More: Medtronic                                                                           

InterSystems Collaborates with ImmunoPrecise Antibodies (IPA) to Combine the Vector Capability of Their Platforms for Healthcare Applications

Read More: InterSystems & ImmunoPrecise Antibodies                      

Related Post:- PharmaShots Weekly Snapshots (March 18 – March 22, 2024)


Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions